Tag: Elranatamab-bcmm

Home / Elranatamab-bcmm

Categories

Elranatamab-bcmm receives accelerated approval by FDA for multiple myeloma

Nov 2023: Elranatamab-bcmm (Elrexfio, Pfizer, Inc.) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager that was given accelerated approval by the Food and Drug Administratio...
elranatamab-bcmm

Scan the code